New Horizons

New Horizons Pharma is a private San Francisco-based early-stage biopharmaceutical company developing therapies centered on aldehyde dehydrogenase 2 (ALDH2). Its lead approach uses intravenous recombinant ALDH2 enzyme therapy to detoxify harmful aldehydes in acute care settings, with programs aimed at ischemia-reperfusion injury in myocardial infarction and several severe alcohol-related conditions. The company also references foundational academic work showing cardioprotective effects of ALDH2 activation and cites Alda-1 as supporting scientific validation for the pathway. New Horizons Pharma appears to be a very small, preclinical company focused on first-in-class emergency and hospital-based applications of ALDH2 biology rather than a broad commercial-stage pipeline.